about
Current status in outpatient parenteral antimicrobial therapy: a practical viewUpdate in Infectious Diseases 2015How should we approach Aspergillus in lung secretions of patients with COPD?Empirical therapeutic approach to infection by resistant gram positive (acute bacterial skin and skin structure infections and health care pneumonia). Value of risk factorsUpdate in Infectious Diseases 2016Resistance to linezolid is mediated by the cfr gene in the first report of an outbreak of linezolid-resistant Staphylococcus aureusDelafloxacin: design, development and potential place in therapyCandidemia in the critically ill patient.Predictive score of haematological toxicity in patients treated with linezolid.Usefulness and prognostic value of biomarkers in patients with community-acquired pneumonia in the emergency department.Transcription Factor GFI1B in Health and Disease.New sepsis criteria: do they replace or complement what is known in the approach to the infectious patient?Update in Infectious Diseases 2017.[Factors predicting failure in empirical antibiotic treatment].Effect of the inadequacy of antibiotic therapy in the Emergency Department on hospital stays.[Usefulness of biomarkers to predict bacteraemia in patients with infection in the emergency department].Key issues in the infected patient care in the Emergency Department.In vitro ceftaroline combinations against meticillin-resistant Staphylococcus aureus.Activity of linezolid and tedizolid against clinical isolates of methicillin-resistant and methicillin and linezolid resistant Staphylococcus aureus: an in vitro comparison.Could ceftaroline be an alternative therapy for linezolid resistant Staphylococcus epidermidis infections in Intensive Care Medicine?A combination of tigecycline, colistin, and meropenem against multidrug-resistant Acinetobacter baumannii bacteremia in a renal transplant recipient: pharmacodynamic and microbiological aspects.Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit.Staphylococcus aureus infections and factors associated with resistance to methicillin in a hospital emergency department.[Antibiotics and timing in infectious disease in the emergency department].In vitro activity of retapamulin against linezolid and methicillin-resistant Staphylococcus aureus isolates.[Endocarditis due to Stenotrophomonas maltophilia].[Candida esophagitis in a non-immunosuppressed patient]A rare cause of pericarditis.[Endotoxin adsortion as adjuvant therapy in gram negative severe sepsis].Correlation between resistance mechanisms in Staphylococcus aureus and cell wall and septum thickening.Useful independent factors for distinguish infection and colonization in patients with urinary carbapenemase-producing Enterobacteriaceae isolation.BAHNG score: predictive model for detection of subjects with the oropharynx colonized by uncommon microorganisms.Update on management of invasive candidiasis.Splenectomy in ITP: we keep removing a healthy functional organ.Monitoring of high-dose fosfomycin guided by NT-proBNP.[Candidemia and invasive candidiasis approach in critically ill patients: role of the echinocandins].[Carotid mycotic pseudoaneurysm. Case report and review].[Interlaboratory controls: more than just a knowledge test].[Palmar ulcer in a splenectomized patient].Current aspects in sepsis approach. Turning things around
P50
Q26750786-CF239885-B195-4CAF-9FA2-02F8CD9C7120Q26781242-720D6F0F-B44F-4AFB-9D0F-20823B5DB3ECQ28068350-E2A78118-A1A6-46C6-B69D-FD6ECCE8A010Q28071286-B87A915C-2F84-434A-B610-C6A66DF2ED08Q28077536-25E65C90-1E2C-4DD1-9E09-474C09A18F9BQ28272797-FD9C595F-04EF-491F-B8EE-AADB0C6AB967Q34554381-4588A8FD-BCD6-42A4-B3C1-2956366BDA6BQ37327111-0DF31143-7EDF-447D-9569-6F9645621AF2Q38876028-39189651-87CC-4A76-A51B-4123D1979F41Q39229864-0504D95A-A1FC-426B-B010-981E976AFC36Q39236509-4FD61CCE-D9C0-4C2A-AF0E-DAEB1C1EB4F6Q40062308-0E9DC409-DA85-4E69-867F-DE4881415382Q40062359-9F0BFD46-BB53-485D-BE36-139BF88EBA3FQ40202338-F3901658-22FF-42DD-8409-217DB392DB87Q40246035-42C3E578-80BE-4959-ACD4-5BA80621D03BQ40301579-5E513B7F-16B3-4DD4-8526-4CE21C725851Q40435306-DE4319A4-F572-4B6A-87AE-D41FC17B4E30Q40565621-2BCCD3D3-3E22-413A-9FAC-CFBAE25EB459Q40626788-07075673-36DA-4992-9980-E05FD1965BCBQ41096187-106B2250-1809-4D84-8811-5A8C64EF2D13Q43013560-F047900E-3C78-4559-995B-38E514F65604Q43041506-32926AED-8CD2-4035-8E00-84D8C64DD465Q43547286-8816EF57-BFD7-4404-BB40-C1EFA6BB207FQ43587403-F35204F6-4F67-407E-8023-A9691A17EDBCQ44098978-489C8506-7DB9-4937-AA43-D505E9478AC0Q44212158-64BC3611-C9F5-4E58-962C-73A1935BDB16Q44252394-DD35B481-B08F-4093-8A35-AF36965F6ADAQ44700403-591C0B38-C4FA-4E3B-846A-D50360259CA9Q44826170-501CF6A7-B21C-4A87-B6DB-CEA2FF32986CQ47133148-117F8A56-C478-4E63-9E30-85BE4F69543AQ47586526-91D68F86-1F27-40B5-B1B7-005109ABC4D6Q47586537-95FD729B-B2A9-4985-BCFB-EE442131F3A5Q47616080-2C2CA77E-94F8-4D28-915C-C77032CD86C7Q48088532-F754C058-50DC-4DC9-916C-41AEC1DCBEB7Q48896645-7468C2C2-55CC-48D3-B598-9D906E33C797Q49850822-DBE3DA90-4C1C-49DB-8D48-0EE2D9407481Q49978907-38DCDBB2-D884-4812-B5BA-90C7BE9A9DC5Q53767503-D7CE148E-B668-417F-9ABD-4436ECA0494DQ54682336-990819A7-EAFD-431D-BEB0-C928D9AEBE7AQ57657199-8BF8BCE7-F599-4B71-9A96-3AF4ABB32662
P50
description
researcher ORCID ID = 0000-0002-9840-6556
@en
wetenschapper
@nl
name
Francisco Javier Candel
@ast
Francisco Javier Candel
@en
Francisco Javier Candel
@es
Francisco Javier Candel
@nl
type
label
Francisco Javier Candel
@ast
Francisco Javier Candel
@en
Francisco Javier Candel
@es
Francisco Javier Candel
@nl
prefLabel
Francisco Javier Candel
@ast
Francisco Javier Candel
@en
Francisco Javier Candel
@es
Francisco Javier Candel
@nl
P106
P21
P31
P496
0000-0002-9840-6556